Sam Martin's Insider Trades & SAST Disclosures
Sam Martin's most recent trade in Celldex Therapeutics Inc. was a trade of 17,172 Common Stock done at an average price of $35.4 . Disclosure was reported to the exchange on June 14, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Sam Martin.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Celldex Therapeutics Inc. | Sam Martin | SVP AND CFO | Sale of securities on an exchange or to another person at price $ 35.42 per share. | 14 Jun 2024 | 17,172 | 28,125 (0%) | 0% | 35.4 | 608,315 | Common Stock |
| Celldex Therapeutics Inc. | Sam Martin | SVP AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.38 per share. | 14 Jun 2024 | 16,968 | 45,297 (0%) | 0% | 10.4 | 176,128 | Common Stock |
| Celldex Therapeutics Inc. | Sam Martin | SVP AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 16,968 | 63,632 | - | - | Incentive Stock Option (Right to Buy) | |
| Celldex Therapeutics Inc. | Sam Martin | SVP AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.02 per share. | 14 Jun 2024 | 3,201 | 28,329 (0%) | 0% | 9.0 | 28,862 | Common Stock |
| Celldex Therapeutics Inc. | Sam Martin | SVP AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 3,201 | 0 | - | - | Incentive Stock Option (Right to Buy) | |
| Celldex Therapeutics Inc. | Sam Martin | SVP AND CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 81,000 | 81,000 | - | - | Incentive Stock Option (right to buy) | |
| Celldex Therapeutics Inc. | Sam Martin | SVP AND CFO | Sale of securities on an exchange or to another person at price $ 34.05 per share. | 30 May 2024 | 35,000 | 25,128 (0%) | 0% | 34.1 | 1,191,775 | Common Stock |
| Celldex Therapeutics Inc. | Sam Martin | SVP AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.38 per share. | 30 May 2024 | 25,000 | 60,128 (0%) | 0% | 10.4 | 259,500 | Common Stock |
| Celldex Therapeutics Inc. | Sam Martin | SVP AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 May 2024 | 25,000 | 80,600 | - | - | Incentive Stock Option (Right to Buy) | |
| Celldex Therapeutics Inc. | Sam Martin | SVP AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.78 per share. | 02 Jan 2024 | 10,750 | 35,128 (0%) | 0% | 2.8 | 29,885 | Common Stock |
| Celldex Therapeutics Inc. | Sam Martin | SVP AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2024 | 10,750 | 0 | - | - | Incentive Stock Option (Right to Buy) | |
| Celldex Therapeutics Inc. | Sam Martin | SVP AND CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 80,000 | 80,000 | - | - | Incentive Stock Option (right to buy) | |
| Leafly Holdings Inc | Samuel Martin | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.73 per share. | 21 Oct 2022 | 1,210 | 337,540 | - | 0.7 | 881 | Common Stock |
| Leafly Holdings Inc | Samuel Martin | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Oct 2022 | 81,758 | 338,750 | - | 0 | Common Stock | |
| Leafly Holdings Inc | Samuel Martin | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 1.51 per share. | 12 Sep 2022 | 26,358 | 53,587 | - | 1.5 | 39,669 | Common Stock |
| Leafly Holdings Inc | Samuel Martin | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2022 | 139,384 | 203,405 | - | - | Restricted Stock Units | |
| Leafly Holdings Inc | Samuel Martin | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2022 | 65,667 | 65,667 | - | 0 | Common Stock | |
| Leafly Holdings Inc | Samuel Martin | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2022 | 64,021 | 64,021 | - | - | Restricted Stock Units | |
| Leafly Holdings Inc | Samuel Martin | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2022 | 1,000 | 66,667 | - | 0 | Common Stock | |
| Celldex Therapeutics Inc. | Sam Martin | SVP AND CFO | Sale of securities on an exchange or to another person at price $ 36.76 per share. | 11 Aug 2022 | 14,261 | 27,664 (0%) | 0% | 36.8 | 524,304 | Common Stock |
| Celldex Therapeutics Inc. | Sam Martin | SVP AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.78 per share. | 11 Aug 2022 | 13,671 | 41,925 (0%) | 0% | 2.8 | 38,005 | Common Stock |
| Celldex Therapeutics Inc. | Sam Martin | SVP AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2022 | 13,671 | 10,750 | - | - | Incentive Stock Option (Right to Buy) | |
| Celldex Therapeutics Inc. | Sam Martin | SVP AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.02 per share. | 11 Aug 2022 | 3,876 | 28,254 (0%) | 0% | 9.0 | 34,948 | Common Stock |
| Celldex Therapeutics Inc. | Sam Martin | SVP AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2022 | 3,876 | 3,201 | - | - | Incentive Stock Option (Right to Buy) | |
| Celldex Therapeutics Inc. | Sam Martin | SVP AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.02 per share. | 11 Aug 2022 | 2,453 | 26,831 (0%) | 0% | 9.0 | 22,117 | Common Stock |
| Celldex Therapeutics Inc. | Sam Martin | SVP AND CFO | Sale of securities on an exchange or to another person at price $ 37.04 per share. | 11 Aug 2022 | 2,453 | 24,378 (0%) | 0% | 37.0 | 90,856 | Common Stock |
| Celldex Therapeutics Inc. | Sam Martin | SVP AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2022 | 2,453 | 7,077 | - | - | Incentive Stock Option (Right to Buy) | |
| Celldex Therapeutics Inc. | Sam Martin | SVP AND CFO | Sale of securities on an exchange or to another person at price $ 35.38 per share. | 11 Aug 2022 | 2,065 | 25,599 (0%) | 0% | 35.4 | 73,053 | Common Stock |
| Celldex Therapeutics Inc. | Sam Martin | SVP AND CFO | Sale of securities on an exchange or to another person at price $ 34.62 per share. | 11 Aug 2022 | 1,221 | 24,378 (0%) | 0% | 34.6 | 42,272 | Common Stock |
| Celldex Therapeutics Inc. | Sam Martin | SVP AND CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 85,000 | 85,000 | - | - | Incentive Stock Option (right to buy) | |
| Celldex Therapeutics Inc. | Sam Martin | SVP and CFO | Sale of securities on an exchange or to another person at price $ 42.00 per share. | 23 Dec 2021 | 9,500 | 24,378 (0%) | 0% | 42 | 399,000 | Common Stock |
| Celldex Therapeutics Inc. | Sam Martin | SVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2021 | 3,750 | 24,421 | - | - | Incentive Stock Option (Right to Buy) | |
| Celldex Therapeutics Inc. | Sam Martin | SVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.78 per share. | 23 Dec 2021 | 3,750 | 33,878 (0%) | 0% | 2.8 | 10,425 | Common Stock |
| Celldex Therapeutics Inc. | Sam Martin | SVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.02 per share. | 23 Dec 2021 | 3,250 | 30,128 (0%) | 0% | 9.0 | 29,304 | Common Stock |
| Celldex Therapeutics Inc. | Sam Martin | SVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2021 | 3,250 | 9,530 | - | - | Incentive Stock Option (Right to Buy) | |
| Celldex Therapeutics Inc. | Sam Martin | SVP and CFO | Sale of securities on an exchange or to another person at price $ 43.92 per share. | 15 Nov 2021 | 7,452 | 28,926 (0%) | 0% | 43.9 | 327,314 | Common Stock |
| Celldex Therapeutics Inc. | Sam Martin | SVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.78 per share. | 15 Nov 2021 | 3,750 | 36,378 (0%) | 0% | 2.8 | 10,425 | Common Stock |
| Celldex Therapeutics Inc. | Sam Martin | SVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2021 | 3,750 | 28,171 | - | - | Incentive Stock Option (Right to Buy) | |
| Celldex Therapeutics Inc. | Sam Martin | SVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2021 | 3,250 | 12,780 | - | - | Incentive Stock Option (Right to Buy) | |
| Celldex Therapeutics Inc. | Sam Martin | SVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.02 per share. | 15 Nov 2021 | 3,250 | 32,628 (0%) | 0% | 9.0 | 29,304 | Common Stock |
| Celldex Therapeutics Inc. | Sam Martin | SVP and CFO | Sale of securities on an exchange or to another person at price $ 42.27 per share. | 15 Nov 2021 | 2,048 | 26,878 (0%) | 0% | 42.3 | 86,569 | Common Stock |
| Celldex Therapeutics Inc. | Sam Martin | SVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2021 | 11,079 | 31,921 | - | - | Incentive Stock Option | |
| Celldex Therapeutics Inc. | Sam Martin | SVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.78 per share. | 10 Aug 2021 | 11,079 | 30,060 (0%) | 0% | 2.8 | 30,800 | Common Stock |
| Celldex Therapeutics Inc. | Sam Martin | SVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.02 per share. | 10 Aug 2021 | 10,302 | 21,037 (0%) | 0% | 9.0 | 92,888 | Common Stock |
| Celldex Therapeutics Inc. | Sam Martin | SVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2021 | 10,302 | 16,030 | - | - | Incentive Stock Option | |
| Celldex Therapeutics Inc. | Sam Martin | SVP and CFO | Sale of securities on an exchange or to another person at price $ 45.25 per share. | 10 Aug 2021 | 2,056 | 18,981 (0%) | 0% | 45.3 | 93,034 | Common Stock |
| Celldex Therapeutics Inc. | Sam Martin | SVP and CFO | Sale of securities on an exchange or to another person at price $ 45.25 per share. | 10 Aug 2021 | 682 | 29,378 (0%) | 0% | 45.3 | 30,861 | Common Stock |
| Celldex Therapeutics Inc. | Sam Martin | SVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 85,000 | 85,000 | - | - | Incentive Stock Option (right to buy) | |
| Celldex Therapeutics Inc. | Sam Martin | SVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2020 | 105,600 | 105,600 | - | - | Incentive Stock Option (right to buy) | |
| Celldex Therapeutics Inc. | Sam Martin | SVP and CFO | Purchase of securities on an exchange or from another person at price $ 3.05 per share. | 09 Jun 2020 | 9,750 | 10,735 (0%) | 0% | 3.1 | 29,738 | Common Stock, par value $0.001 per share |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges